156 related articles for article (PubMed ID: 29672299)
1. CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.
Liu T; Yan Z; Liu Y; Choy E; Hornicek FJ; Mankin H; Duan Z
Cell Physiol Biochem; 2018; 46(3):1218-1230. PubMed ID: 29672299
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells.
Xiao Z; Wan J; Nur AA; Dou P; Mankin H; Liu T; Ouyang Z
Cell Physiol Biochem; 2018; 51(4):1879-1893. PubMed ID: 30504723
[TBL] [Abstract][Full Text] [Related]
3. Silencing of CD44 gene expression in human 143-B osteosarcoma cells promotes metastasis of intratibial tumors in SCID mice.
Gvozdenovic A; Arlt MJ; Campanile C; Brennecke P; Husmann K; Born W; Muff R; Fuchs B
PLoS One; 2013; 8(4):e60329. PubMed ID: 23565227
[TBL] [Abstract][Full Text] [Related]
4. Cluster of differentiation 44 promotes osteosarcoma progression in mice lacking the tumor suppressor Merlin.
Ma J; Klemm J; Gerardo-Ramírez M; Frappart L; Castven D; Becker D; Zoch A; Parent R; Bartosch B; Minnich K; Giovannini M; Danckwardt S; Hartmann N; Morrison H; Herrlich P; Marquardt JU; Hartmann M
Int J Cancer; 2020 Nov; 147(9):2564-2577. PubMed ID: 32525563
[TBL] [Abstract][Full Text] [Related]
5. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
6. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis.
Luu HH; Kang Q; Park JK; Si W; Luo Q; Jiang W; Yin H; Montag AG; Simon MA; Peabody TD; Haydon RC; Rinker-Schaeffer CW; He TC
Clin Exp Metastasis; 2005; 22(4):319-29. PubMed ID: 16170668
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of CD44 inhibits proliferation, migration and invasion of osteosarcoma cells accompanied by downregulation of cathepsin S.
Kong L; Ji H; Gan X; Cao S; Li Z; Jin Y
J Orthop Surg Res; 2022 Mar; 17(1):154. PubMed ID: 35264209
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-mediated silencing of CD44: unveiling the role of hyaluronic acid-mediated interactions in cancer drug resistance.
Xu Z
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):2849-2876. PubMed ID: 37991544
[TBL] [Abstract][Full Text] [Related]
9. CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.
Gerardo-Ramírez M; Keggenhoff FL; Giam V; Becker D; Groth M; Hartmann N; Straub BK; Morrison H; Galle PR; Marquardt JU; Herrlich P; Hartmann M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955749
[TBL] [Abstract][Full Text] [Related]
10. Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library.
Wu Y; Zhou L; Wang Z; Wang X; Zhang R; Zheng L; Kang T
Cancer Biol Med; 2020 Aug; 17(3):782-794. PubMed ID: 32944406
[No Abstract] [Full Text] [Related]
11. Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system.
Feng Y; Sassi S; Shen JK; Yang X; Gao Y; Osaka E; Zhang J; Yang S; Yang C; Mankin HJ; Hornicek FJ; Duan Z
J Orthop Res; 2015 Feb; 33(2):199-207. PubMed ID: 25348612
[TBL] [Abstract][Full Text] [Related]
12. CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma.
Gao Y; Feng Y; Shen JK; Lin M; Choy E; Cote GM; Harmon DC; Mankin HJ; Hornicek FJ; Duan Z
Sci Rep; 2015 Jun; 5():11365. PubMed ID: 26079799
[TBL] [Abstract][Full Text] [Related]
13. CD44 enhances tumor formation and lung metastasis in experimental osteosarcoma and is an additional predictor for poor patient outcome.
Gvozdenovic A; Arlt MJ; Campanile C; Brennecke P; Husmann K; Li Y; Born W; Muff R; Fuchs B
J Bone Miner Res; 2013 Apr; 28(4):838-47. PubMed ID: 23169460
[TBL] [Abstract][Full Text] [Related]
14. In vivo gene transfer between interacting human osteosarcoma cell lines is associated with acquisition of enhanced metastatic potential.
Tome Y; Tsuchiya H; Hayashi K; Yamauchi K; Sugimoto N; Kanaya F; Tomita K; Hoffman RM
J Cell Biochem; 2009 Oct; 108(2):362-7. PubMed ID: 19623575
[TBL] [Abstract][Full Text] [Related]
15. The tetraspanin CD81 mediates the growth and metastases of human osteosarcoma.
Mizoshiri N; Shirai T; Terauchi R; Tsuchida S; Mori Y; Hayashi D; Kishida T; Arai Y; Mazda O; Nakanishi T; Kubo T
Cell Oncol (Dordr); 2019 Dec; 42(6):861-871. PubMed ID: 31494861
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of CD44 expression in osteosarcoma: evidence from six studies.
Liu Y; Wu Y; Gu S; Sun Z; Rui Y; Wang J; Lu Y; Li H; Xu K; Sheng P
Diagn Pathol; 2014 Aug; 9():140. PubMed ID: 25112408
[TBL] [Abstract][Full Text] [Related]
17. [The role of CD44 in the proliferation, adhesiveness and invasiveness of osteosarcoma cell lines].
Peng TS; Qiu JS; Li Z; Zhang M; Liang HZ
Zhonghua Bing Li Xue Za Zhi; 2005 Jun; 34(6):362-6. PubMed ID: 16185508
[TBL] [Abstract][Full Text] [Related]
18. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.
Liao Y; Chen L; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
Oncotarget; 2017 May; 8(18):30276-30287. PubMed ID: 28415820
[TBL] [Abstract][Full Text] [Related]
19. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma.
Liang C; Li F; Wang L; Zhang ZK; Wang C; He B; Li J; Chen Z; Shaikh AB; Liu J; Wu X; Peng S; Dang L; Guo B; He X; Au DWT; Lu C; Zhu H; Zhang BT; Lu A; Zhang G
Biomaterials; 2017 Dec; 147():68-85. PubMed ID: 28938163
[TBL] [Abstract][Full Text] [Related]
20. HAS3-related hyaluronan enhances biological activities necessary for metastasis of osteosarcoma cells.
Tofuku K; Yokouchi M; Murayama T; Minami S; Komiya S
Int J Oncol; 2006 Jul; 29(1):175-83. PubMed ID: 16773198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
